Cipla Limited has successfully concluded its postal ballot process, with shareholders approving all four proposed resolutions with strong majorities. The pharmaceutical company announced the results on 26th March, 2026, following the completion of the e-voting process that concluded on 25th March, 2026.

Leadership Appointments Approved

Shareholders demonstrated strong support for the company's leadership changes, approving the appointment of Mr Achin Gupta (DIN: 09491674) in multiple capacities. The voting results showed overwhelming approval across all shareholder categories.

Voting Participation and Process

The postal ballot process witnessed significant shareholder participation, with 650905507 votes cast representing 80.58% of the total outstanding shares of 807780677. The e-voting facility was provided by National Securities Depository Limited (NSDL), ensuring a transparent and efficient voting process.

Shareholder Category Participation

Scrutinizer's Oversight

The voting process was overseen by Mr Avinash Bagul, Partner at M/s BNP & Associates, who was appointed as scrutinizer through a Board Resolution dated 23rd January, 2026. The scrutinizer confirmed that all resolutions were passed with requisite majorities and that the e-voting process was conducted in a fair and transparent manner.

The postal ballot notice was sent to 574481 members whose email addresses were registered with the company, out of a total of 591086 members as on the record date of 20th February, 2026. The e-voting period commenced on 24th February, 2026 at 9.00 a.m. and concluded on 25th March, 2026 at 5.00 p.m.

Regulatory Compliance

The postal ballot process was conducted in compliance with Section 108 and Section 110 of the Companies Act, 2013, along with relevant rules and SEBI Listing Regulations. The company published advertisements in "Business Standard" English newspaper and "Sakal" Marathi newspaper on 24th February, 2026, providing requisite information to shareholders.

The voting results and scrutinizer's report have been uploaded on the company's website at www.cipla.com and on NSDL's e-voting platform at www.evoting.nsdl.com , ensuring transparency and accessibility for all stakeholders.

Cipla has informed stock exchanges about the resignation of a key executive from its leadership team. The pharmaceutical company announced that Mr. Pradeep Bhadauria, Global Chief Scientific Officer, will be leaving the organization to pursue opportunities outside the company.

Executive Departure Details

The resignation announcement provides specific details about Bhadauria's departure from the pharmaceutical giant:

Regulatory Communication

Cipla filed the resignation notice on March 26, 2026, through proper regulatory channels. The announcement was simultaneously communicated to multiple stock exchanges where the company's shares are listed. Company Secretary Rajendra Chopra signed the official communication, ensuring compliance with disclosure requirements.

Leadership Structure Impact

Bhadauria held dual responsibilities within Cipla's organizational structure. As Global Chief Scientific Officer, he was responsible for the company's scientific strategy and research initiatives. Additionally, his role as a member of the Management Council positioned him as part of the senior leadership team involved in strategic decision-making processes.

The executive's employment through Cipla USA Inc., a wholly owned subsidiary, reflects the company's global operational structure. This arrangement allows Cipla to manage its international operations while maintaining oversight of key personnel across different geographical locations.

Transition Timeline

The resignation becomes effective on March 31, 2026, providing the company with a defined timeline for transition planning. This advance notice allows Cipla to manage the leadership change systematically and ensure continuity in its scientific operations and strategic initiatives.